Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties And Methods Of Administering The Same

Patent No. EP2611423 (titled "Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties And Methods Of Administering The Same") was filed by Glaxosmithkline on Aug 31, 2011. The application was issued on Sep 21, 2022.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKMar 24, 2016FRKELLY
TEVA UK LIMITEDMar 24, 2016ELKINGTON AND FIFE
OSERMar 23, 2016MAIWALD PATENT- UND RECHTSANWALTSGESELLSCHAFT MBH

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2611423

GLAXOSMITHKLINE
Application Number
EP11755043A
Filing Date
Aug 31, 2011
Status
Patent Maintained As Amended
Aug 19, 2022
Publication Date
Sep 21, 2022